当前蛋白身份:P03420 重新检索
本组结构的主要差异维度
构建体不同 突变/修饰不同 组装状态不同 配体/离子不同 实验方法不同 实验环境不同 结构质量指标不同

差异标签只比较当前检索结果;所有PDB和assembly原始记录仍分别保留。

相关结构差异明细

一行代表一个 PDB 条目中的一个 biological assembly;同一蛋白的多个单体会分别列出。

PDB 条目 Assembly / 聚集状态 构建体 突变与修饰 配体、离子与非聚合物 实验方法 实验环境 结构质量
29QJ Respiratory syncytial virus fusion protein N-terminal heptad repeat domain in complex with Double stapled peptide 4/4g 提交 2026-03-30 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 6 PDB 声明:hexameric(6) 与蛋白数一致
链 A 159–209(51 aa)
非标准单体:是(mmCIF未提供具体位点) 未记录非水小分子 X-RAY DIFFRACTION mmCIF 未提供已读取条件 分辨率 1.32 Å R-free 0.232
3IXT Crystal Structure of Motavizumab Fab Bound to Peptide Epitope 提交 2009-09-04 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 P 254–277(24 aa) 片段:sequence database residues 254-277
非标准单体:是(mmCIF未提供具体位点) EDO 1,2-ETHANEDIOL × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 6.5;293 K;17.5% PEG 8000, 0.2 M zinc acetate, 0.1 M cacodylate pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
分辨率 2.75 Å R-free 0.274
3IXT Crystal Structure of Motavizumab Fab Bound to Peptide Epitope 提交 2009-09-04 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 C 254–277(24 aa) 片段:sequence database residues 254-277
非标准单体:是(mmCIF未提供具体位点) EDO 1,2-ETHANEDIOL × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 6.5;293 K;17.5% PEG 8000, 0.2 M zinc acetate, 0.1 M cacodylate pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
分辨率 2.75 Å R-free 0.274
3KPE Solution structure of the respiratory syncytial virus (RSV)six-helix bundle complexed with TMC353121, a small-moleucule inhibitor of RSV 提交 2009-11-16 Assembly 1 蛋白同源多聚体 同源多聚体;蛋白 × 6 PDB 声明:hexameric(6) 与蛋白数一致
链 A 159–209(51 aa) 片段:proteinase K-resistant core of heptad repeat 1
链 B 482–520(39 aa) 片段:proteinase K-resistant core of heptad repeat 2
未记录 TM3 2-[[6-[[[2-(3-hydroxypropyl)-5-methylphenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl-3-pyridinol × 3 PG4 TETRAETHYLENE GLYCOL × 3 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7.5;293 K;30% (v/v) PEG-400 + 100 mM HEPES, pH 7.5 + 200 mM NaCl, VAPOR DIFFUSION, SITTING DROP, temperature 293K
分辨率 1.47 Å R-free 0.196
3O41 Crystal Structure of 101F Fab Bound to 15-mer Peptide Epitope 提交 2010-07-26 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 P 422–436(15 aa) 片段:Residues 422-436
非标准单体:是(mmCIF未提供具体位点) SO4 SULFATE ION × 8 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 8.5;293 K;20.5% (w/v) PEG 4000, 0.2 M lithium sulfate monohydrate, 0.1 M Tris-HCl pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
分辨率 1.95 Å R-free 0.217
3O41 Crystal Structure of 101F Fab Bound to 15-mer Peptide Epitope 提交 2010-07-26 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 C 422–436(15 aa) 片段:Residues 422-436
非标准单体:是(mmCIF未提供具体位点) SO4 SULFATE ION × 6 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 8.5;293 K;20.5% (w/v) PEG 4000, 0.2 M lithium sulfate monohydrate, 0.1 M Tris-HCl pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
分辨率 1.95 Å R-free 0.217
3O45 Crystal Structure of 101F Fab Bound to 17-mer Peptide Epitope 提交 2010-07-26 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 P 422–438(17 aa) 片段:UNP residues 422-438
非标准单体:是(mmCIF未提供具体位点) SO4 SULFATE ION × 4 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 8.5;293 K;20.5% (w/v) PEG 4000, 0.2 M lithium sulfate monohydrate, 0.1 M Tris-HCl pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
分辨率 2.87 Å R-free 0.254
3O45 Crystal Structure of 101F Fab Bound to 17-mer Peptide Epitope 提交 2010-07-26 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 C 422–438(17 aa) 片段:UNP residues 422-438
非标准单体:是(mmCIF未提供具体位点) SO4 SULFATE ION × 3 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 8.5;293 K;20.5% (w/v) PEG 4000, 0.2 M lithium sulfate monohydrate, 0.1 M Tris-HCl pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
分辨率 2.87 Å R-free 0.254
3RKI Structural basis for immunization with post-fusion RSV F to elicit high neutralizing antibody titers 提交 2011-04-18 Assembly 1 其他组合 同源多聚体;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 A 1–524(524 aa) 片段:Respiratory Syncytial Virus F, residues 1-524
链 B 1–524(524 aa) 片段:Respiratory Syncytial Virus F, residues 1-524
链 C 1–524(524 aa) 片段:Respiratory Syncytial Virus F, residues 1-524
未记录 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 5.1;298 K;4.2 M Sodium Formate, 100 mM Sodium Acetate, pH 5.1, VAPOR DIFFUSION, HANGING DROP, temperature 298K
分辨率 3.20 Å R-free 0.264
4JHW Crystal Structure of Respiratory Syncytial Virus Fusion Glycoprotein Stabilized in the Prefusion Conformation by Human Antibody D25 提交 2013-03-05 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 9 PDB 声明:nonameric(9) 与蛋白数一致
链 F 26–109(84 aa)
链 F 137–513(377 aa)
突变:P102A, I379V, M447V 突变:P102A, I379V, M447V 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7.5;293 K;30% (w/v) PEG 400, 3.75% (w/v) PEG 3350, 0.1 M HEPES pH 7.5, and 1% (v/v) 1,2-butanediol, VAPOR DIFFUSION, HANGING DROP, temperature 293K
分辨率 3.60 Å R-free 0.267
4MMQ Crystal Structure of Prefusion-stabilized RSV F Variant DS 提交 2013-09-09 Assembly 1 信息不足 异源复合物;蛋白 × 6 PDB 声明:hexameric(6) 与蛋白数一致
链 A 26–107(82 aa)
链 B 137–513(377 aa)
突变:P102A 突变:S155C, S290C, I379V, M447V SO4 SULFATE ION × 18 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 9.5;298 K;1.4 M K/Na tartrate, 0.1M CHES pH 9.5, 0.2 M LiSO4, VAPOR DIFFUSION, HANGING DROP, temperature 298K
分辨率 3.25 Å R-free 0.274
4MMR Crystal Structure of Prefusion-stabilized RSV F Variant Cav1 at pH 9.5 提交 2013-09-09 Assembly 1 信息不足 异源复合物;蛋白 × 6 PDB 声明:hexameric(6) 与蛋白数一致
链 A 26–107(82 aa)
链 B 137–513(377 aa)
突变:P102A 突变:S190F, V207L, I379V, M447V 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 9.5;293 K;1.4M sodium potassium tartarate, 0.1M CHES, pH 9.5, 0.2M Li2SO4, VAPOR DIFFUSION, HANGING DROP, temperature 293K
分辨率 3.10 Å R-free 0.264
4MMS Crystal Structure of Prefusion-stabilized RSV F Variant Cav1 at pH 5.5 提交 2013-09-09 Assembly 1 信息不足 异源复合物;蛋白 × 6 PDB 声明:hexameric(6) 与蛋白数一致
链 A 26–107(82 aa)
链 B 137–513(377 aa)
链 C 26–107(82 aa)
链 D 137–513(377 aa)
链 E 26–107(82 aa)
链 F 137–513(377 aa)
突变:P102A 突变:S190F, V207L, I379V, M447V 突变:P102A 突变:S190F, V207L, I379V, M447V 突变:P102A 突变:S190F, V207L, I379V, M447V SO4 SULFATE ION × 14 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 5.5;298 K;1.7 M ammonium sulfate, 0.1 M citrate pH 5.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
分辨率 2.40 Å R-free 0.214
4MMT Crystal Structure of Prefusion-stabilized RSV F Variant DS-Cav1 at pH 9.5 提交 2013-09-09 Assembly 1 信息不足 异源复合物;蛋白 × 6 PDB 声明:hexameric(6) 与蛋白数一致
链 A 26–107(82 aa)
链 B 137–513(377 aa)
突变:P102A 突变:S155C, S190F, V207L, S290C, I379V, M447V 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 9.5;1.8 M Na/K tartrate, 0.2 M LiSO4, 0.1 M CHES pH9.5, VAPOR DIFFUSION, HANGING DROP
分辨率 3.05 Å R-free 0.243
4MMU Crystal Structure of Prefusion-stabilized RSV F Variant DS-Cav1 at pH 5.5 提交 2013-09-09 Assembly 1 信息不足 异源复合物;蛋白 × 6 PDB 声明:hexameric(6) 与蛋白数一致
链 A 26–107(82 aa)
链 B 137–513(377 aa)
突变:P102A 突变:S155C, S190F, V207L, S290C, I379V, M447V SO4 SULFATE ION × 12 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3 PO4 PHOSPHATE ION × 3 X-RAY DIFFRACTION
X-ray结晶条件 pH 5.5;1.8 M Ammonium sulphate 0.1 M citrate pH5.5, VAPOR DIFFUSION, HANGING DROP
分辨率 3.00 Å R-free 0.228
4MMV Crystal Structure of Prefusion-stabilized RSV F Variant DS-Cav1-TriC at pH 9.5 提交 2013-09-09 Assembly 1 信息不足 异源复合物;蛋白 × 6 PDB 声明:hexameric(6) 与蛋白数一致
链 A 26–107(82 aa)
链 B 137–513(377 aa)
突变:P102A 突变:S155C, S190F, V207L, S290C, I379V, M447, VD486H, E487Q, F488W, D489H 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 9.5;293 K;1.4M sodium potassium tartarate, 0.1M CHES, pH 9.5, 0.2M Li2SO4, VAPOR DIFFUSION, HANGING DROP, temperature 293K
分辨率 2.81 Å R-free 0.279
4ZYP Crystal Structure of Motavizumab and Quaternary-Specific RSV-Neutralizing Human Antibody AM14 in Complex with Prefusion RSV F Glycoprotein 提交 2015-05-21 Assembly 1 信息不足 异源复合物;蛋白 × 15 PDB 声明:pentadecameric(15) 与蛋白数一致
链 A 26–513(488 aa)
链 B 26–513(488 aa)
链 C 26–513(488 aa)
突变:S155C, S190F, V207L, S290C, I379V, M447V 突变:S155C, S190F, V207L, S290C, I379V, M447V 突变:S155C, S190F, V207L, S290C, I379V, M447V 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 6.5;293 K;5.645mg/mL EndoH digested DS-Cav1 + AM14 Fab + Motavizumab Fab, 11.4% PEG8000, 1.71% MPD, 0.1M Imidazole pH 6.5
分辨率 5.50 Å R-free 0.277
5C69 Crystal Structure of Prefusion-stabilized RSV F variant PR-DM 提交 2015-06-22 Assembly 1 信息不足 同源多聚体;蛋白 × 6 PDB 声明:hexameric(6) 与蛋白数一致
链 A 26–518(493 aa) 片段:F2 subunit, F1 subunit ectodomain
突变:N67I, S215P, I379V, M447V SO4 SULFATE ION × 42 NHE 2-[N-CYCLOHEXYLAMINO]ETHANE SULFONIC ACID × 12 CL CHLORIDE ION × 30 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION;pH 9.5;293 K;1.24M K/Na tartrate, 0.2M LiSO4, 0.1M CHES pH 9.5
分辨率 2.30 Å R-free 0.217
5C6B Crystal Structure of Prefusion-stabilized RSV F variant SC-TM 提交 2015-06-22 Assembly 1 信息不足 同源多聚体;蛋白 × 6 PDB 声明:hexameric(6) 与蛋白数一致
链 F 26–513(488 aa) 片段:ectodomain
突变:N67I, S215P, E487Q, I379V, M447V,N67I, S215P, E487Q, I379V, M447V NHE 2-[N-CYCLOHEXYLAMINO]ETHANE SULFONIC ACID × 6 SO4 SULFATE ION × 24 CL CHLORIDE ION × 12 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION;pH 9.5;293 K;1.34M K/Na tartrate, 0.2M LiSO4, 0.1M CHES pH 9.5
分辨率 2.40 Å R-free 0.211
5EA3 Crystal Structure of Inhibitor JNJ-2408068 in Complex with Prefusion RSV F Glycoprotein 提交 2015-10-15 Assembly 1 蛋白同源多聚体 同源多聚体;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 F 1–513(513 aa) 片段:RSV F ectodomain (UNP residues 1-513)
突变:V207L, S190F, S155C, S290C NHE 2-[N-CYCLOHEXYLAMINO]ETHANE SULFONIC ACID × 3 SO4 SULFATE ION × 18 5NK 2-[[2-[[1-(2-azanylethyl)piperidin-4-yl]amino]-4-methyl-benzimidazol-1-yl]methyl]-6-methyl-pyridin-3-ol × 3 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 9.5;293 K;1.54 M potassium/sodium tartrate, 0.2 M lithium sulfate, 0.1 M CHES, pH 9.5
分辨率 2.75 Å R-free 0.229
5EA4 Crystal Structure of Inhibitor JNJ-49153390 in Complex with Prefusion RSV F Glycoprotein 提交 2015-10-15 Assembly 1 蛋白同源多聚体 同源多聚体;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 F 1–513(513 aa) 片段:RSV F ectodomain (UNP residues 1-513)
突变:S190F, V207L, S155C, S290C NHE 2-[N-CYCLOHEXYLAMINO]ETHANE SULFONIC ACID × 3 SO4 SULFATE ION × 15 5NM 3-[[5-bromanyl-1-(3-methylsulfonylpropyl)benzimidazol-2-yl]methyl]-1-cyclopropyl-imidazo[4,5-c]pyridin-2-one × 3 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 9.5;293 K;1.54 M potassium/sodium tartrate, 0.2 M lithium sulfate, 0.1 M CHES, pH 9.5
分辨率 2.30 Å R-free 0.214
5EA5 Crystal Structure of Inhibitor TMC-353121 in Complex with Prefusion RSV F Glycoprotein 提交 2015-10-15 Assembly 1 蛋白同源多聚体 同源多聚体;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 F 1–513(513 aa) 片段:RSV F ectodomain (UNP residues 1-513)
突变:S190F, V207L, S155C, S290C NHE 2-[N-CYCLOHEXYLAMINO]ETHANE SULFONIC ACID × 3 TM3 2-[[6-[[[2-(3-hydroxypropyl)-5-methylphenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl-3-pyridinol × 3 SO4 SULFATE ION × 3 TAR D(-)-TARTARIC ACID × 3 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 9.5;293 K;1.54 M potassium/sodium tartrate, 0.2 M lithium sulfate, 0.1 M CHES, pH 9.5
分辨率 3.05 Å R-free 0.248
5EA6 Crystal Structure of Inhibitor BTA-9881 in Complex with Prefusion RSV F Glycoprotein 提交 2015-10-15 Assembly 1 蛋白同源多聚体 同源多聚体;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 F 1–513(513 aa) 片段:RSV F ectodomain (UNP residues 1-513)
突变:S190F, V207L, S155C, S290C NHE 2-[N-CYCLOHEXYLAMINO]ETHANE SULFONIC ACID × 3 SO4 SULFATE ION × 12 5NP (9~{b}~{R})-9~{b}-(4-chlorophenyl)-1-pyridin-3-ylcarbonyl-2,3-dihydroimidazo[5,6]pyrrolo[1,2-~{a}]pyridin-5-one × 3 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 9.5;293 K;1.54 M potassium/sodium tartrate, 0.2 M lithium sulfate, 0.1 M CHES, pH 9.5
分辨率 2.75 Å R-free 0.235
5EA7 Crystal Structure of Inhibitor BMS-433771 in Complex with Prefusion RSV F Glycoprotein 提交 2015-10-15 Assembly 1 蛋白同源多聚体 同源多聚体;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 F 1–513(513 aa) 片段:RSV F ectodomain (UNP residues 1-513)
突变:S190F, V207L, S155C, S290C SO4 SULFATE ION × 15 NHE 2-[N-CYCLOHEXYLAMINO]ETHANE SULFONIC ACID × 3 5NO 1-cyclopropyl-3-[[1-(4-oxidanylbutyl)benzimidazol-2-yl]methyl]imidazo[4,5-c]pyridin-2-one × 3 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 9.5;293 K;1.54 M potassium/sodium tartrate, 0.2 M lithium sulfate, 0.1 M CHES, pH 9.5
分辨率 2.85 Å R-free 0.241
5EA8 Crystal Structure of Prefusion RSV F Glycoprotein Fusion Inhibitor Resistance Mutant D489Y 提交 2015-10-15 Assembly 1 蛋白同源多聚体 同源多聚体;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 F 1–513(513 aa) 片段:RSV F ectodomain (UNP residues 1-513)
突变:S190F, V207L, S155C, S290C, D489Y SO4 SULFATE ION × 15 NHE 2-[N-CYCLOHEXYLAMINO]ETHANE SULFONIC ACID × 3 TAR D(-)-TARTARIC ACID × 3 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 9.5;293 K;1.54 M potassium/sodium tartrate, 0.2 M lithium sulfate, 0.1 M CHES, pH 9.5
分辨率 2.60 Å R-free 0.237
5J3D Crystal structure of human Fab 14N4 in complex with post-fusion RSV F 提交 2016-03-30 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 12 PDB 声明:dodecameric(12) 与蛋白数一致
链 E 26–98(73 aa) 片段:UNP residues 26-98
链 F 147–513(367 aa) 片段:UNP residues 147-513
链 G 26–98(73 aa) 片段:UNP residues 26-98
链 I 147–513(367 aa) 片段:UNP residues 147-513
链 J 26–98(73 aa) 片段:UNP residues 26-98
链 K 147–513(367 aa) 片段:UNP residues 147-513
未记录 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION;293 K;2 M ammonium sulfate, 5% 2-propanol
分辨率 4.08 Å R-free 0.282
5K6B Crystal structure of prefusion-stabilized RSV F single-chain 9 DS-Cav1 variant. 提交 2016-05-24 Assembly 1 蛋白同源多聚体 同源多聚体;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 F 26–105(80 aa) 片段:UNP residues 26-105 linked to residues 145-509 via LINKER residues GS
链 F 145–509(365 aa) 片段:UNP residues 26-105 linked to residues 145-509 via LINKER residues GS
未记录 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3 SO4 SULFATE ION × 12 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 5.5;293 K;0.1 M NaOAc-Acetic Acid pH 5.5, 1.09 M Li2SO4, 0.12 M MgSO4, 3.33 % (w/v) PEG 400
分辨率 2.98 Å R-free 0.260
5K6C Crystal structure of prefusion-stabilized RSV F single-chain 9-10 DS-Cav1 variant. 提交 2016-05-24 Assembly 1 蛋白同源多聚体 同源多聚体;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 F 26–103(78 aa) 片段:UNP residues 26-101 linked to residues 145-509 via LINKER residues ATGS
链 F 145–509(365 aa) 片段:UNP residues 26-101 linked to residues 145-509 via LINKER residues ATGS
未记录 SO4 SULFATE ION × 3 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7.5;293 K;0.1 M HEPES pH 7.5, 0.19 M (NH4)2SO4, 11 % iso-propanol, 17 % PEG 8,000
分辨率 3.58 Å R-free 0.262
5K6F Crystal structure of prefusion-stabilized RSV F single-chain 9-19 DS-Cav1 variant. 提交 2016-05-24 Assembly 1 蛋白同源多聚体 同源多聚体;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 F 26–103(78 aa) 片段:UNP residues 26-103 linked to residues 145-509 via LINKER residues GGSGGSG
链 F 145–509(365 aa) 片段:UNP residues 26-103 linked to residues 145-509 via LINKER residues GGSGGSG
未记录 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;293 K;0.1 M Na citrate pH 5.6, 15 % iso-propanol, 17 % PEG 4,000
分辨率 2.59 Å R-free 0.237
5K6G Crystal structure of prefusion-stabilized RSV F single-chain 9-24 DS-Cav1 variant. 提交 2016-05-24 Assembly 1 蛋白同源多聚体 同源多聚体;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 F 26–96(71 aa) 片段:UNP residues 26-79 and UNP residues 145-509 linked via LINKER residues GS
链 F 145–509(365 aa) 片段:UNP residues 26-79 and UNP residues 145-509 linked via LINKER residues GS
未记录 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;293 K;0.1 M NaOAc-Acetic Acid pH 5.5, 1.82 M Li2SO4, 0.1 M MgSO4, 5 % (w/v) PEG 400
分辨率 2.90 Å R-free 0.287
5K6H Crystal structure of prefusion-stabilized RSV F single-chain 9-10 DS-Cav1 A149C-Y458C variant. 提交 2016-05-24 Assembly 1 蛋白同源多聚体 同源多聚体;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 F 26–103(78 aa) 片段:UNP residues 26-103 linked to residues 145-509 via LINKER residues GS
链 F 145–509(365 aa) 片段:UNP residues 26-103 linked to residues 145-509 via LINKER residues GS
未记录 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;293 K;0.1 M phosphate-citrate, pH4.2, 0.12 M NaCl, 9.5% (w/v) PEG 8,000
分辨率 2.65 Å R-free 0.252
5K6I Crystal structure of prefusion-stabilized RSV F single-chain 9-10 DS-Cav1 A149C-Y458C, S46G-E92D-S215P-K465Q variant. 提交 2016-05-24 Assembly 1 蛋白同源多聚体 同源多聚体;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 F 26–103(78 aa) 片段:UNP residues 26-103 and residues 145-509 linked via LINKER residues GS
链 F 145–509(365 aa) 片段:UNP residues 26-103 and residues 145-509 linked via LINKER residues GS
未记录 ZN ZINC ION × 6 EDO 1,2-ETHANEDIOL × 6 PO4 PHOSPHATE ION × 3 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 6 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;293 K;0.1M Na Cacodylate, pH 6.5, 0.2M ZnAC, 17% (w/v) PEG 8,000
分辨率 2.92 Å R-free 0.253
5TOJ Crystal structure of the RSV F glycoprotein in complex with the neutralizing single-domain antibody F-VHH-4 提交 2016-10-17 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 6 PDB 声明:hexameric(6) 与蛋白数一致
链 A 1–513(513 aa)
链 B 1–513(513 aa)
链 C 1–513(513 aa)
突变:S155C, S190F, V207L, S290C, I379V, M447V 突变:S155C, S190F, V207L, S290C, I379V, M447V 突变:S155C, S190F, V207L, S290C, I379V, M447V NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 4.5;293 K;2.45 mg/mL EndoH-digested DS-Cav1 + F-VHH-4, 14.75% w/v PEG3350, 8.8% v/v isopropanol, 0.2 M ammonium citrate
分辨率 3.30 Å R-free 0.234
5TOK Crystal structure of the RSV F glycoprotein in complex with the neutralizing single-domain antibody F-VHH-L66 提交 2016-10-17 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 6 PDB 声明:hexameric(6) 与蛋白数一致
链 A 1–513(513 aa)
链 B 1–513(513 aa)
链 C 1–513(513 aa)
突变:S155C, S190F, V207L, S290C, I379V, M447V 突变:S155C, S190F, V207L, S290C, I379V, M447V 突变:S155C, S190F, V207L, S290C, I379V, M447V NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3 PO4 PHOSPHATE ION × 1 X-RAY DIFFRACTION
X-ray结晶条件 LIQUID DIFFUSION;293 K;4.79 mg/mL EndoH-digested DS-Cav1 + F-VHH-L66, 0.05 M potassium phosphate, 20% w/v PEG4000
分辨率 3.80 Å R-free 0.286
5TPN Crystal structure of RSV F in complex with human antibody hRSV90 提交 2016-10-20 Assembly 1 信息不足 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 A 27–513(487 aa)
突变:N67I, S215P, I379V, M447V 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;293 K;30% PEG, 400/200 mM MgCl2, 6H2O/100 mM HEPES pH 7.5
分辨率 3.14 Å R-free 0.262
5U68 Structural basis for antibody cross-neutralization of respiratory syncytial virus and human metapneumovirus 提交 2016-12-07 Assembly 1 信息不足 异源复合物;蛋白 × 6 PDB 声明:hexameric(6) 与蛋白数一致
链 A 1–513(513 aa) 片段:UNP P03420 residues 1-513,UNP M1E1E4 residues 1-28
链 B 1–513(513 aa) 片段:UNP P03420 residues 1-513,UNP M1E1E4 residues 1-28
链 C 1–513(513 aa) 片段:UNP P03420 residues 1-513,UNP M1E1E4 residues 1-28
未记录 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;295 K;0.1M Potassium Nitrate, 0.1M Citrate Phosphate pH 4.2, 1 % Tacsimate pH 7.0, 14 (w/v) % PEG 6000
分辨率 3.08 Å R-free 0.239
5UDC Crystal Structure of RSV F A2 Bound to MEDI8897 提交 2016-12-26 Assembly 1 其他组合 异源复合物;蛋白 × 9 PDB 声明:nonameric(9) 与蛋白数一致
链 A 1–513(513 aa)
链 D 1–513(513 aa)
链 F 1–513(513 aa)
突变:S155C, S290C, S190F, V207L 突变:S155C, S290C, S190F, V207L 突变:S155C, S290C, S190F, V207L CL CHLORIDE ION × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 8.5;293 K;10% w/v PEG8000, 20% v/v ethylene glycol, 0.1 M Tris/BICINE pH 8.5, 0.02 M carboxylic acids, 0.3 M NDSB-195
分辨率 3.45 Å R-free 0.232
5W23 Crystal Structure of RSV F in complex with 5C4 Fab 提交 2017-06-05 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 9 PDB 声明:nonameric(9) 与蛋白数一致
链 A 1–513(513 aa) 片段:UNP residues 1-513
链 B 1–513(513 aa) 片段:UNP residues 1-513
链 C 1–513(513 aa) 片段:UNP residues 1-513
未记录 ZN ZINC ION × 8 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 6.5;293 K;Seed stock: 0.01 M zinc sulfate heptahydrate, 0.1 M MES hydrate pH 6.5, 22.5% v/v PEG MME 550 and 0.5% w/v polyvinylpyrrolidone K15 Reservoir solution: 0.2 M ammonium acetate, 0.1 M BIS-TRIS pH 6.5 and 25% PEG 3350
分辨率 3.40 Å R-free 0.239
6CXC 3.9A Cryo-EM structure of murine antibody bound at a novel epitope of respiratory syncytial virus fusion protein 提交 2018-04-02 Assembly 1 信息不足 异源复合物;蛋白 × 12 PDB 声明:dodecameric(12) 与蛋白数一致
链 A 26–526(501 aa)
链 B 26–526(501 aa)
链 C 26–526(501 aa)
链 D 26–526(501 aa)
链 E 26–526(501 aa)
链 F 26–526(501 aa)
未记录 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 6 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7
cryo-EM玻璃化条件 冷冻剂 NITROGEN
分辨率 3.90 Å
6DC3 RSV prefusion F bound to RSD5 Fab 提交 2018-05-04 Assembly 1 信息不足 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 F 1–513(513 aa)
未记录 SO4 SULFATE ION × 13 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;293 K;1.8 M Lithium sulfate, 0.1 M Tris pH 8.0
分辨率 3.50 Å R-free 0.205
6DC5 RSV prefusion F in complex with AM22 Fab 提交 2018-05-04 Assembly 1 信息不足 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 A 1–513(513 aa)
未记录 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 CD CADMIUM ION × 1 PEG DI(HYDROXYETHYL)ETHER × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 5.5;293 K;32% PEG 400, 4% PEG 3350, 0.01 M cadmium chloride, 0.1 M sodium acetate pH 5.5
分辨率 3.50 Å R-free 0.280
6DC5 RSV prefusion F in complex with AM22 Fab 提交 2018-05-04 Assembly 2 信息不足 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 D 1–513(513 aa)
未记录 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 CD CADMIUM ION × 1 PEG DI(HYDROXYETHYL)ETHER × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 5.5;293 K;32% PEG 400, 4% PEG 3350, 0.01 M cadmium chloride, 0.1 M sodium acetate pH 5.5
分辨率 3.50 Å R-free 0.280
6DC5 RSV prefusion F in complex with AM22 Fab 提交 2018-05-04 Assembly 3 信息不足 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 G 1–513(513 aa)
未记录 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 CD CADMIUM ION × 1 PEG DI(HYDROXYETHYL)ETHER × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 5.5;293 K;32% PEG 400, 4% PEG 3350, 0.01 M cadmium chloride, 0.1 M sodium acetate pH 5.5
分辨率 3.50 Å R-free 0.280
6OE4 Prefusion RSV F monomer bound by neutralizing antibody CR9501 提交 2019-03-27 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 A 1–513(513 aa)
突变:S155C, S290C EDO 1,2-ETHANEDIOL × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;293 K;4.2mg/mL monomeric prefusion F (DS-Cav1) + CR9501 Fab, 14.3% (w/v) PEG8000, 2.4% (v/v) 2-methyl-2,4-pentanediol (MPD), 0.1 M sodium citrate pH 5.5, 0.1 M sodium malonate pH 7.0
分辨率 3.30 Å R-free 0.259
6OE4 Prefusion RSV F monomer bound by neutralizing antibody CR9501 提交 2019-03-27 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 D 1–513(513 aa)
突变:S155C, S290C EDO 1,2-ETHANEDIOL × 3 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;293 K;4.2mg/mL monomeric prefusion F (DS-Cav1) + CR9501 Fab, 14.3% (w/v) PEG8000, 2.4% (v/v) 2-methyl-2,4-pentanediol (MPD), 0.1 M sodium citrate pH 5.5, 0.1 M sodium malonate pH 7.0
分辨率 3.30 Å R-free 0.259
6OE5 Splayed open prefusion RSV F captured by CR9501 and motavizumab Fabs 提交 2019-03-27 Assembly 1 信息不足 异源复合物;蛋白 × 5 PDB 声明:pentameric(5) 与蛋白数一致
链 A 1–513(513 aa)
突变:N67I, S215P 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;293 K;4.69 mg/mL prefusion F (PR-DM) + motavizumab Fab + CR9501 Fab, 30% (v/v) PEG400, 0.19 M ammonium sulfate, 3.1% (w/v) PEG8000, 0.1 M Tris pH 8.5
分辨率 4.10 Å R-free 0.306
6OUS Structure of fusion glycoprotein from human respiratory syncytial virus 提交 2019-05-05 Assembly 1 信息不足 异源复合物;蛋白 × 12 PDB 声明:dodecameric(12) 与蛋白数一致
链 A 26–109(84 aa)
链 B 137–513(377 aa)
链 C 26–109(84 aa)
链 D 137–513(377 aa)
链 E 26–109(84 aa)
链 F 137–513(377 aa)
非标准单体:是(mmCIF未提供具体位点) 非标准单体:是(mmCIF未提供具体位点) 非标准单体:是(mmCIF未提供具体位点) NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7.5;293 K;100 mM Tris 8.5, 10% PEG 8000, 200 mM ammonium sulfate
分辨率 3.40 Å R-free 0.275
6OUS Structure of fusion glycoprotein from human respiratory syncytial virus 提交 2019-05-05 Assembly 2 信息不足 异源复合物;蛋白 × 12 PDB 声明:dodecameric(12) 与蛋白数一致
链 G 26–109(84 aa)
链 H 137–513(377 aa)
链 I 26–109(84 aa)
链 J 137–513(377 aa)
链 K 26–109(84 aa)
链 L 137–513(377 aa)
非标准单体:是(mmCIF未提供具体位点) 非标准单体:是(mmCIF未提供具体位点) 非标准单体:是(mmCIF未提供具体位点) NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7.5;293 K;100 mM Tris 8.5, 10% PEG 8000, 200 mM ammonium sulfate
分辨率 3.40 Å R-free 0.275
6W52 Prefusion RSV F bound by neutralizing antibody RSB1 提交 2020-03-12 Assembly 1 信息不足 异源复合物;蛋白 × 4 PDB 声明:tetrameric(4) 与蛋白数一致
链 A 26–107(82 aa)
未记录 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;293.15 K;0.1 M Hepes pH 7.5, 25% PEG 2000 MME, 0.01 M spermidine
分辨率 3.74 Å R-free 0.286
7MMN Crystal Structure of the Prefusion RSV F Glycoprotein bound by human antibody AM14 提交 2021-04-29 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 12 PDB 声明:dodecameric(12) 与蛋白数一致
链 A 26–97(72 aa)
链 B 137–513(377 aa)
链 C 26–97(72 aa)
链 I 137–513(377 aa)
链 J 26–97(72 aa)
链 K 137–513(377 aa)
未记录 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;293.15 K;0.2M NaCl, 0.1M MES pH 6.0, 20% w/v PEG 2000 MME
分辨率 3.57 Å R-free 0.245
8KG5 Prefusion RSV F Bound to Lonafarnib and D25 Fab 提交 2023-08-17 Assembly 1 信息不足 异源复合物;蛋白 × 5 PDB 声明:pentameric(5) 与蛋白数一致
链 A 1–513(513 aa)
链 B 1–513(513 aa)
链 C 1–513(513 aa)
未记录 336 4-{2-[4-(3,10-DIBROMO-8-CHLORO-6,11-DIHYDRO-5H-BENZO[5,6]CYCLOHEPTA[1,2-B]PYRIDIN-11-YL)PIPERIDIN-1-YL]-2-OXOETHYL}PIPERIDINE-1-CARBOXAMIDE × 3 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.5
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 3.17 Å
8ULJ Prefusion RSV F bound by neutralizing antibody 2E08 提交 2023-10-16 Assembly 1 信息不足 异源复合物;蛋白 × 12 PDB 声明:dodecameric(12) 与蛋白数一致
链 A 26–104(79 aa)
未记录 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;293.15 K;23.64%w/v PEG 1500, 0.1 M MMT buffer (DL-malic acid:MES:Tris base at a molar ratio of 1:2:2) with pH 4.36
分辨率 3.00 Å R-free 0.264
8ULK Prefusion RSV F bound by neutralizing antibody 1G12 提交 2023-10-16 Assembly 1 信息不足 异源复合物;蛋白 × 12 PDB 声明:dodecameric(12) 与蛋白数一致
链 A 26–97(72 aa)
链 B 26–97(72 aa)
链 C 26–97(72 aa)
未记录 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;293.15 K;0.2 M Sodium sulfate, 20 % w/v PEG 3350
分辨率 4.28 Å R-free 0.279
9HVW Respiratory Syncytial Virus Fusion protein in the postfusion conformation in complex with monoclonal antibody 131-2a Fab 提交 2025-01-02 Assembly 1 信息不足 异源复合物;蛋白 × 8 PDB 声明:octameric(8) 与蛋白数一致
链 A 26–105(80 aa)
链 B 26–105(80 aa)
链 C 26–105(80 aa)
链 D 137–515(379 aa)
链 E 137–515(379 aa)
链 F 137–515(379 aa)
未记录 未记录非水小分子 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.4
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 3.10 Å
9LM5 Cryo-EM structure of prefusion-stabilized RSV F (DS-Cav1 strain: A2) in complex with nanobody 1G9 提交 2025-01-18 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 6 PDB 声明:hexameric(6) 与蛋白数一致
链 A 1–513(513 aa)
链 B 1–513(513 aa)
链 C 1–513(513 aa)
未记录 未记录非水小分子 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.5
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 2.77 Å
9LM6 Cryo-EM structure of prefusion-stabilized RSV F (DS-Cav1 strain: A2) in complex with nanobody 1D8 提交 2025-01-18 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 6 PDB 声明:hexameric(6) 与蛋白数一致
链 A 1–513(513 aa)
链 B 1–513(513 aa)
链 C 1–513(513 aa)
未记录 未记录非水小分子 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.5
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 3.26 Å
9MKN Structure of the Respiratory Syncytial Virus Fusion Protein Bound to Human Antibodies RSV_2245 and RSV_3301 提交 2024-12-17 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 18 PDB 声明:octadecameric(18) 与蛋白数一致
链 A 27–96(70 aa)
链 B 137–506(370 aa)
链 C 27–96(70 aa)
链 D 137–506(370 aa)
链 E 27–96(70 aa)
链 F 137–506(370 aa)
突变:I379V, M447V variant 突变:I379V, M447V variant 突变:I379V, M447V variant 未记录非水小分子 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 8
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 3.40 Å
9RA5 Respiratory syncytial virus fusion protein N-terminal heptad repeat domain in complex with Double stapled peptide 3/4i 提交 2025-05-20 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 6 PDB 声明:hexameric(6) 与蛋白数一致
链 A 159–209(51 aa)
非标准单体:是(mmCIF未提供具体位点) 未记录非水小分子 X-RAY DIFFRACTION mmCIF 未提供已读取条件 分辨率 1.62 Å R-free 0.207
9U74 Respiratory Syncytial Virus pre-F trimer bound by neutralizing antibody PR306007 提交 2025-03-24 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 8 PDB 声明:octameric(8) 与蛋白数一致
链 A 26–103(78 aa)
链 B 137–513(377 aa)
链 C 26–103(78 aa)
链 D 137–513(377 aa)
链 E 26–103(78 aa)
链 F 137–513(377 aa)
未记录 未记录非水小分子 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.2
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 4.08 Å
9WDP Cyro-EM structure of prefusion RSV fusion glycoprotein in complex with Ziresovir and motavizumab Fab 提交 2025-08-19 Assembly 1 信息不足 异源复合物;蛋白 × 9 PDB 声明:nonameric(9) 与蛋白数一致
链 A 1–513(513 aa)
链 B 1–513(513 aa)
链 C 1–513(513 aa)
未记录 A1EV1 ~{N}-[(3-azanyloxetan-3-yl)methyl]-2-[1,1-bis(oxidanylidene)-3,5-dihydro-2~{H}-1$l^{6},4-benzothiazepin-4-yl]-6-methyl-quinazolin-4-amine × 1 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.5
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 3.27 Å